Continuing Medical Education Information

Instructions for Participation

To receive up to 1.5 AMA PRA category 1 credits for this activity:

• Read the case summary on the front of the newsletter
• Answer and fax back the questions on the back cover
• Read the remainder of the case study inside the newsletter
• Complete the CME posttest answer and evaluation form at the end of the newsletter, and fax or mail these back to the address listed by September 15, 2006
• 70% of your posttest answers must be correct for you to receive a certificate of credit

Target Audience:

Dermatologists, dermatologic surgeons, surgical and medical oncologists, oncology nurses, primary care physicians, and other health care professionals who treat or screen for melanoma

Learning Objectives:

• Compare and contrast therapies for the management of stage IIC melanoma
• Describe the factors affecting the prognosis of stage IV melanoma
• List the advantages/disadvantages of aggressive staging approaches in stage IV melanoma
• Evaluate the role of palliative surgical techniques in patients with multisite metastatic melanoma
• List the factors to consider in discussing palliative care and hospice with a patient with metastatic melanoma

Accreditation and Credit Designation:

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this continuing medical education activity for a maximum of 1.5 category 1 credits towards the AMA Physicians Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

*Other healthcare professionals are awarded 0.15 continuing education units (CEUs), which are equal to 1.5 contact hours.

We gratefully acknowledge an educational grant from Schering-Plough in support of this program.

Faculty and Disclosure:

Merrick I. Ross, MD
Professor of Surgical Oncology, University of Texas
M.D. Anderson Cancer Center
Houston, Texas
*Speakers Bureau and Honoraria: Schering Corporation

Kenneth K. Tanabe, MD
Chief, Division of Surgical Oncology
Massachusetts General Hospital, Associate Professor of Surgery
Harvard Medical School, Boston, Massachusetts
*No relationships to disclose

Faculty for this activity have been required to disclose all financial or other relationships with pharmaceutical companies, biomedical device manufacturers, and other healthcare-related for-profit entities.

The faculty acknowledges the discussion of off-label use of pharmaceuticals, specifically regarding high-dose interferon alfa-2B

Date of Original Release:
September 15, 2005

Expiration Date:
September 15, 2006

Date of Last Review:
September 15, 2005

Disclaimer
The materials provided at this site are for informational purposes and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented on this site are solely those of the authors and do not necessarily represent those of the University of Pittsburgh or of those of UPMC Health System. References to any non-University of Pittsburgh entity or non-UPMC Health System entity, product, service, or source of information in this site should not be considered an endorsement, either direct or implied, by the University of Pittsburgh or by UPMC Health System. The University of Pittsburgh and UPMC Health System accepts no liability for the content of any pages referenced in this site.

Privacy Policy
The Melanoma Care Consortium is committed to protecting the privacy of those who choose to participate in the program (herein referred to as "Web site"), located at https://www.melanomacare.org/, to earn CME credits. This policy describes the security of the website, the safeguarding of personal information, and the collection and use of personal information.

Security
Safeguarding your personal information
Physical, and procedural safeguards are in place to protect unauthorized access to personal information used to access the website.

Collection and use of your personal information
In order to earn CME credits utilizing the Web site, the submission of certain personally identifiable information is necessary. The required items include the last five digits of the participant's Social Security number, first name, last name, degree, and e-mail address. These items are necessary to award and track the credits participants may earn after completing the program. Participants are asked to complete an evaluation of the site. All evaluative information submitted is collected and retained. Evaluative information assists the staff of MelanomaCare in continuously improving the learning experience.

MelanomaCare does not transfer, sell, or share personal information with outside parties. MelanomaCare will not otherwise disclose personal information unless required to in a legal process.

RDCME staff members review individual test results to the extent necessary to record and track participant's credits.

If you have any questions or comments on this click here.

Contacting the Provider
If you have any questions about this CME activity, you may contact the provider directly by calling (412)647-8232 or via email at [email protected].

Read this Case Study